Improvement of cardiovascular outcomes in patients with advanced chronic kidney disease. In easily understood language, this is Heart and blood vessel disease and Kidney disease.
Conditions
Brief summary
•CV death, • non-fatal myocardial infarction, • stroke, or • PAD events
Detailed description
1.3-point MACE , 2.All-cause death, 3.Composite of all-cause death,non-fatal myocardial infarction,or stroke, 4.Composite of all-cause death, non-fatal myocardial infarction, or stroke, or peripheral artery disease event, 5.Individual components of the composite outcomes, 6.Net-clinical-benefit outcome 7. Venous thromboembolism.
Interventions
DRUGMatching placebo for BAY 597939 2.5 mg filmcoated tablets
Sponsors
The George Institute For Global Health
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| •CV death, • non-fatal myocardial infarction, • stroke, or • PAD events | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.3-point MACE , 2.All-cause death, 3.Composite of all-cause death,non-fatal myocardial infarction,or stroke, 4.Composite of all-cause death, non-fatal myocardial infarction, or stroke, or peripheral artery disease event, 5.Individual components of the composite outcomes, 6.Net-clinical-benefit outcome 7. Venous thromboembolism. | — |
Countries
Belgium, France, Germany
Outcome results
None listed